Assessing Patient-Reported Outcomes in People with Myelodysplastic Syndromes: Can a Customized Selection of Items from the EORTC Library Enhance the EORTC QLQ-C30?

CONCLUSIONSOur data shows how incorporating the patient voice early on in PRO measurement selection and a conceptually-driven approach to the development of customized item sets can lead to more fit-for-purpose PRO measures to be used in the context of clinical trials of patients with cancer. Specifically, while the QLQ-C30 may be a satisfactory PRO instrument for use in people with hematological stem cell disorders, it can be made more targeted and disease-specific by carefully utilizing mixed methods and selecting supplemental items from the EORTC item library. This patient-reported online survey provides early evidence, in a small sample of patients, on the appropriateness of both the original QLQ-C30 and enhanced item sets to assess PROs in HR MDS/CMML, and AML and should be further analyzed in future research.DisclosuresBell: Takeda Pharmaceuticals: Employment, Equity Ownership. Pompilus: Modus Outcomes: Employment; Takeda Pharmaceuticals: Research Funding. Christian: Modus Outcomes: Employment; Takeda Pharmaceuticals: Research Funding. Mazerolle: Modus Outcomes: Employment; Takeda Pharmaceuticals: Research Funding. Scipione: Takeda Pharmaceuticals: Employment. Bejar: Takeda: Research Funding; Celgene: Consultancy, Honoraria; Foundation Medicine: Consultancy; Modus Outcomes: Consultancy; Genoptix: Consultancy; AbbVie/Genentech: Consultancy, Honoraria; Astex/Otsuka: Consultancy, Honoraria. Galaznik: Takeda Pharmaceuticals International Co.: Employment. Fram: Takeda Pharma...

Source: Blood - November 21, 2018 Category: Hematology Authors: Bell, J. A., Pompilus, F. A., Christian, A., Mazerolle, F., Scipione, F., Bejar, R., Galaznik, A., Fram, R. J., Faller, D. V., Cano, S., Regnault, A. Tags: 904. Outcomes Research-Malignant Conditions: Poster III Source Type: research